These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 17954367

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy.
    Horita Y, Taura K, Taguchi T, Furusu A, Kohno S.
    Nephrology (Carlton); 2006 Oct; 11(5):462-6. PubMed ID: 17014562
    [Abstract] [Full Text] [Related]

  • 4. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
    Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, Tang AW, Wong TY, Yung CY, Yung JC, Yu AW, Szeto CC, HKVIN Study Group.
    Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
    [Abstract] [Full Text] [Related]

  • 5. Effect of red wine on urinary protein, 8-hydroxydeoxyguanosine, and liver-type fatty acid-binding protein excretion in patients with diabetic nephropathy.
    Nakamura T, Fujiwara N, Sugaya T, Ueda Y, Koide H.
    Metabolism; 2009 Aug; 58(8):1185-90. PubMed ID: 19481229
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Successful treatment of combination therapy using an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker in a patient with IgA nephropathy].
    Horino T, Ito H, Tanimoto N, Yoshida T, Sasaoka A, Chijiwa T, Hosokawa T, Hashimoto K.
    Nihon Jinzo Gakkai Shi; 2003 Aug; 45(2):104-8. PubMed ID: 12703406
    [Abstract] [Full Text] [Related]

  • 8. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy.
    Ogawa S, Takeuchi K, Mori T, Nako K, Tsubono Y, Ito S.
    Hypertens Res; 2007 Apr 20; 30(4):325-34. PubMed ID: 17541211
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy.
    Nakamura T, Sugaya T, Node K, Ueda Y, Koide H.
    Am J Kidney Dis; 2006 Mar 20; 47(3):439-44. PubMed ID: 16490622
    [Abstract] [Full Text] [Related]

  • 16. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep 20; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
    Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C, Conte G.
    Am J Kidney Dis; 2008 Sep 20; 52(3):475-85. PubMed ID: 18468748
    [Abstract] [Full Text] [Related]

  • 19. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K.
    Hypertens Res; 2009 Jul 20; 32(7):575-80. PubMed ID: 19444280
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.